ea0081oc3.4 | Oral Communications 3: Thyroid 1 | ECE2022
Durante Cosimo
, Robinson Bruce
, Sherman Steven I
, Krajewska Jolanta
, Lin Chia-Chi
, Vaisman Fernanda
, Hoff Ana O
, Hitre Erika
, Bowles Daniel W
, Hernando Jorge
, Banerjee Kamalika
, Levytskyy Roman M
, Oliver Jennifer W
, Keam Bhumsuk
, Capdevila Jaume
, Brose Marcia
Background: Increasing age is associated with poorer survival in DTC [Oyer SL, 2012]. In the phase 3 COSMIC-311 trial (NCT03690388), cabozantinib, an inhibitor of VEGFR2, MET, AXL and RET, significantly improved the progression-free survival (PFS) vs placebo in previously treated patients with RAI-R DTC (HR 0.22, 96% CI 0.13-0.36; P<0.0001; median follow-up 6.2 months). The impact of age on efficacy and safety was included in the prespecified subgroup analysis.</p...